Literature DB >> 1313052

Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin.

M J Bale1, R N Jones, M E Erwin, F P Koontz, E H Gerlach, P R Murray, J A Washington.   

Abstract

A multilaboratory study to determine disk diffusion quality control ranges for Haemophilus influenzae ATCC 49247 and five investigational drugs was performed. Multiple lots of Haemophilus Test Medium and antibiotic disks were used for replicate testing in conformance with the recommendations of the National Committee for Clinical Laboratory Standards. Quality control disk zone diameter ranges were proposed for cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1313052      PMCID： PMC265148          DOI： 10.1128/jcm.30.3.744-745.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.

Authors:  M S Barrett; R N Jones; M E Erwin; D M Johnson; B M Briggs
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Sep-Oct       Impact factor: 2.803

2.  Quality control limits for disk diffusion and broth microdilution susceptibility tests with Haemophilus test medium.

Authors:  G V Doern; E H Gerlach; J H Jorgensen; P R Murray; C Thornsberry; J A Washington
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Nov-Dec       Impact factor: 2.803

3.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

4.  Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.

Authors:  H C Neu; G Saha; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

5.  Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; L A Maher; A W Howell
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

6.  Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors:  D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

7.  MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.

Authors:  M J Bale; R N Jones; M E Erwin; F P Koontz; E H Gerlach; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

8.  Antibacterial activity of trospectomycin (U-63366F) and initial evaluations of disk diffusion susceptibility tests.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

9.  In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.

Authors:  K Hirai; H Aoyama; M Hosaka; Y Oomori; Y Niwata; S Suzue; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191
  9 in total
  2 in total

1.  Quality control guidelines for cefdinir, cefepime, cefetamet, cefmetazole, cefpodoxime, cefprozil, and clinafloxacin (CI-960) for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Quality Control Study Group.

Authors:  M J Bale; R N Jones
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

2.  Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests with Haemophilus influenzae.

Authors:  M S Barrett; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.